RESUMEN
Dengue is the most important arboviral disease world-wide with an estimated 400 million annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for dengue seropositive individuals aged 9-45 years. There is great need for a dengue vaccine that could be given to dengue-naïve individuals and very young children. To that end, the U.S. NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach evaluating the safety, infectivity, and immunogenicity of different candidates. This approach identified poor candidates who were then discarded from further evaluation. Each of the components of the tetravalent vaccine formulation is able to replicate to very low titer, inducing a homotypic immune response to each. The immune response elicited by the tetravalent vaccine is balanced, without immunodominance of one component. The vaccine was licensed by several manufacturers for development, including the Instituto Butantan which initiated a Phase 3 efficacy trial.
Asunto(s)
Vacunas contra el Dengue/inmunología , Virus del Dengue/inmunología , Dengue/prevención & control , Desarrollo de Medicamentos , Vacunas Atenuadas/inmunología , Dengue/historia , Dengue/inmunología , Dengue/virología , Vacunas contra el Dengue/administración & dosificación , Vacunas contra el Dengue/genética , Vacunas contra el Dengue/historia , Virus del Dengue/genética , Desarrollo de Medicamentos/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/genética , Vacunas Atenuadas/historia , Vacunas Combinadas/administración & dosificación , Vacunas Combinadas/genética , Vacunas Combinadas/historia , Vacunas Combinadas/inmunologíaRESUMEN
Although viruses and bacteria have been known as agents of diseases since 1546, 250 years went by until the first vaccines against these pathogens were developed (1796 and 1800s). In contrast, Malaria, which is a protozoan-neglected disease, has been known since the 5th century BCE and, despite 2,500 years having passed since then, no human vaccine has yet been licensed for Malaria. Additionally, no modern human vaccine is currently licensed against Visceral or Cutaneous leishmaniasis. Vaccination against Malaria evolved from the inoculation of irradiated sporozoites through the bite of Anopheles mosquitoes in 1930's, which failed to give protection, to the use of controlled human Malaria infection (CHMI) provoked by live sporozoites of Plasmodium falciparum and curtailed with specific chemotherapy since 1940's. Although the use of CHMI for vaccination was relatively efficacious, it has some ethical limitations and was substituted by the use of injected recombinant vaccines expressing the main antigens of the parasite cycle, starting in 1980. Pre-erythrocytic (PEV), Blood stage (BSV), transmission-blocking (TBV), antitoxic (AT), and pregnancy-associated Malaria vaccines are under development. Currently, the RTS,S-PEV vaccine, based on the circumsporozoite protein, is the only one that has arrived at the Phase III trial stage. The "R" stands for the central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP); the "T" for the T-cell epitopes of the CSP; and the "S" for hepatitis B surface antigen (HBsAg). In Africa, this latter vaccine achieved only 36.7% vaccine efficacy (VE) in 5-7 years old children and was associated with an increase in clinical cases in one assay. Therefore, in spite of 35 years of research, there is no currently licensed vaccine against Malaria. In contrast, more progress has been achieved regarding prevention of leishmaniasis by vaccine, which also started with the use of live vaccines. For ethical reasons, these were substituted by second-generation subunit or recombinant DNA and protein vaccines. Currently, there is one live vaccine for humans licensed in Uzbekistan, and four licensed veterinary vaccines against visceral leishmaniasis: Leishmune® (76-80% VE) and CaniLeish® (68.4% VE), which give protection against strong endpoints (severe disease and deaths under natural conditions), and, under less severe endpoints (parasitologically and PCR-positive cases), Leishtec® developed 71.4% VE in a low infective pressure area but only 35.7% VE and transient protection in a high infective pressure area, while Letifend® promoted 72% VE. A human recombinant vaccine based on the Nucleoside hydrolase NH36 of Leishmania (L.) donovani, the main antigen of the Leishmune® vaccine, and the sterol 24-c-methyltransferase (SMT) from L. (L.) infantum has reached the Phase I clinical trial phase but has not yet been licensed against the disease. This review describes the history of vaccine development and is focused on licensed formulations that have been used in preventive medicine. Special attention has been given to the delay in the development and licensing of human vaccines against Protozoan infections, which show high incidence worldwide and still remain severe threats to Public Health.
Asunto(s)
Leishmania donovani/inmunología , Vacunas contra la Leishmaniasis/historia , Leishmaniasis Visceral/prevención & control , Concesión de Licencias/historia , Vacunas contra la Malaria/historia , Malaria Falciparum/prevención & control , Vacunación Masiva/historia , Plasmodium falciparum/inmunología , Adulto , Animales , Niño , Preescolar , Femenino , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Leishmaniasis/inmunología , Leishmaniasis Visceral/parasitología , Leishmaniasis Visceral/veterinaria , Vacunas contra la Malaria/inmunología , Malaria Falciparum/parasitología , Vacunación Masiva/métodos , Embarazo , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Vivas no Atenuadas/historia , Vacunas Vivas no Atenuadas/inmunología , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunologíaRESUMEN
Porcine reproductive and respiratory syndrome (PRRS) caused by PRRS virus (PRRSV) was reported in the late 1980s. PRRS still is a huge economic concern to the global pig industry with a current annual loss estimated at one billion US dollars in North America alone. It has been 20 years since the first modified live-attenuated PRRSV vaccine (PRRSV-MLV) became commercially available. PRRSV-MLVs provide homologous protection and help in reducing shedding of heterologous viruses, but they do not completely protect pigs against heterologous field strains. There have been many advances in understanding the biology and ecology of PRRSV; however, the complexities of virus-host interaction and PRRSV vaccinology are not yet completely understood leaving a significant gap for improving breadth of immunity against diverse PRRS isolates. This review provides insights on immunization efforts using infectious PRRSV-based vaccines since the 1990s, beginning with live PRRSV immunization, development and commercialization of PRRSV-MLV, and strategies to overcome the deficiencies of PRRSV-MLV through use of replicating viral vectors expressing multiple PRRSV membrane proteins. Finally, powerful reverse genetics systems (infectious cDNA clones) generated from more than 20 PRRSV isolates of both genotypes 1 and 2 viruses have provided a great resource for exploring many innovative strategies to improve the safety and cross-protective efficacy of live PRRSV vaccines. Examples include vaccines with diminished ability to down-regulate the immune system, positive and negative marker vaccines, multivalent vaccines incorporating antigens from other porcine pathogens, vaccines that carry their own cytokine adjuvants, and chimeric vaccine viruses with the potential for broad cross-protection against heterologous strains. To combat this devastating pig disease in the future, evaluation and commercialization of such improved live PRRSV vaccines is a shared goal among PRRSV researchers, pork producers and biologics companies.
Asunto(s)
Síndrome Respiratorio y de la Reproducción Porcina/epidemiología , Síndrome Respiratorio y de la Reproducción Porcina/prevención & control , Virus del Síndrome Respiratorio y Reproductivo Porcino/inmunología , Vacunas Virales/inmunología , Animales , Descubrimiento de Drogas/historia , Descubrimiento de Drogas/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Síndrome Respiratorio y de la Reproducción Porcina/inmunología , Virus del Síndrome Respiratorio y Reproductivo Porcino/genética , Porcinos , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Virales/administración & dosificación , Vacunas Virales/historiaRESUMEN
Brunenders, a type I poliovirus (PV) strain, was developed in 1952 by J. F. Enders and colleagues through serial in vitro passaging of the parental Brunhilde strain, and was reported to display partial neuroattenuation in monkeys. This phenotype of attenuation encouraged two vaccine manufacturers to adopt Brunenders as the type I component for their inactivated poliovirus vaccines (IPVs) in the 1950s, although today no licensed IPV vaccine contains Brunenders. Here we confirmed, in a transgenic mouse model, the report of Enders on the reduced neurovirulence of Brunenders. Although dramatically neuroattenuated relative to WT PV strains, Brunenders remains more virulent than the attenuated oral vaccine strain, Sabin 1. Importantly, the neuroattenuation of Brunenders does not affect in vitro growth kinetics and in vitro antigenicity, which were similar to those of Mahoney, the conventional type I IPV vaccine strain. We showed, by full nucleotide sequencing, that Brunhilde and Brunenders differ at 31 nucleotides, eight of which lead to amino acid changes, all located in the capsid. Upon exchanging the Brunenders capsid sequence with that of the Mahoney capsid, WT neurovirulence was regained in vivo, suggesting a role for the capsid mutations in Brunenders attenuation. To date, as polio eradication draws closer, the switch to using attenuated strains for IPV is actively being pursued. Brunenders preceded this novel strategy as a partially attenuated IPV strain, accompanied by decades of successful use in the field. Providing data on the attenuation of Brunenders may be of value in the further construction of attenuated PV strains to support the grand pursuit of the global eradication of poliomyelitis.
Asunto(s)
Poliomielitis/prevención & control , Vacuna Antipolio Oral/inmunología , Poliovirus/inmunología , Secuencia de Aminoácidos , Animales , Historia del Siglo XX , Humanos , Ratones , Datos de Secuencia Molecular , Pruebas de Neutralización , Poliomielitis/historia , Poliomielitis/inmunología , Poliomielitis/virología , Poliovirus/genética , Poliovirus/crecimiento & desarrollo , Vacuna Antipolio Oral/química , Vacuna Antipolio Oral/genética , Vacuna Antipolio Oral/historia , Alineación de Secuencia , Vacunas Atenuadas/química , Vacunas Atenuadas/genética , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunologíaRESUMEN
After Edward Jenner established human vaccination over 200 years ago, attenuated poxviruses became key players to contain the deadliest virus of its own family: Variola virus (VARV), the causative agent of smallpox. Cowpox virus (CPXV) and horsepox virus (HSPV) were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia virus (VACV), which was used in the final campaigns aimed to eradicate the disease, an endeavor that was accomplished by the World Health Organization (WHO) in 1980. Ever since, naturally evolved strains used for vaccination were introduced into research laboratories where VACV and other poxviruses with improved safety profiles were generated. Recombinant DNA technology along with the DNA genome features of this virus family allowed the generation of vaccines against heterologous diseases, and the specific insertion and deletion of poxvirus genes generated an even broader spectrum of modified viruses with new properties that increase their immunogenicity and safety profile as vaccine vectors. In this review, we highlight the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.
Asunto(s)
Vacuna contra Viruela/historia , Vacuna contra Viruela/aislamiento & purificación , Viruela/prevención & control , Animales , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Poxviridae/inmunología , Poxviridae/aislamiento & purificación , Vacuna contra Viruela/inmunología , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/aislamiento & purificación , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
Live attenuated vaccines against human viral diseases have been amongst the most successful cost effective interventions in medical history. Smallpox was declared eradicated in 1980; poliomyelitis is nearing global eradication and measles has been controlled in most parts of the world. Vaccines function well for acute diseases such as these but chronic infections such as HIV are more challenging for reasons of both likely safety and probable efficacy. The derivation of the vaccines used has in general not been purely rational except in the sense that it has involved careful clinical trials of candidates and subsequent careful follow up in clinical use; the identification of the candidates is reviewed.
Asunto(s)
Vacunas Atenuadas/inmunología , Vacunas Atenuadas/aislamiento & purificación , Vacunas Virales/inmunología , Vacunas Virales/aislamiento & purificación , Virosis/prevención & control , Ensayos Clínicos como Asunto , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas Atenuadas/historia , Vacunas Virales/historia , Virosis/inmunologíaRESUMEN
Vaccines have a history that started late in the 18th century. From the late 19th century, vaccines could be developed in the laboratory. However, in the 20th century, it became possible to develop vaccines based on immunologic markers. In the 21st century, molecular biology permits vaccine development that was not possible before.
Asunto(s)
Vacunación/historia , Técnicas de Cultivo de Célula/historia , Ingeniería Genética/historia , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Virus Reordenados/genética , Vacunas Atenuadas/historia , Vacunas de Productos Inactivados/historia , Vacunas de Subunidad/historia , Vacunas Virales/historiaRESUMEN
Vaccination against influenza represents our most effective form of prevention. Historical approaches toward vaccine creation and production have yielded highly effective vaccines that are safe and immunogenic. Despite their effectiveness, these historical approaches do not allow for the incorporation of changes into the vaccine in a timely manner. In 2013, a recombinant protein-based vaccine that induces immunity toward the influenza virus hemagglutinin was approved for use in the USA. This vaccine represents the first approved vaccine formulation that does not require an influenza virus intermediate for production. This review presents a brief history of influenza vaccines, with insight into the potential future application of vaccines generated using recombinant technology.
Asunto(s)
Descubrimiento de Drogas/tendencias , Vacunas contra la Influenza/inmunología , Vacunas contra la Influenza/aislamiento & purificación , Tecnología Farmacéutica/tendencias , Descubrimiento de Drogas/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Influenza/historia , Gripe Humana/prevención & control , Tecnología Farmacéutica/historia , Estados Unidos , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/aislamiento & purificación , Vacunas de Productos Inactivados/historia , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/aislamiento & purificación , Vacunas de Subunidad/historia , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/aislamiento & purificación , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
In 1958 Poliomyelitis Institute in Moscow and Institute of Experimental Medicine in St. Petersburg received from A. Sabin the attenuated strains of poliomyelitis virus. The characteristics of the strains were thoroughly studied by A. A. Smorodintsev and coworkers. They found that the virulence of the strains fluctuated slightly in 10 consecutive passages through the intestine of the non-immune children. A part of the Sabin material was used by A. A. Smorodintsev and M. P. Chumakov in the beginning of 1959 for immunizing approximately 40000 children in Estonia, Lithuania, and Latvia. Epidemic poliomyelitis rate in these republics decreased from approximately 1000 cases yearly before vaccination to less than 20 in the third quarter of 1959. This was a convincing proof of the efficacy and safety of the vaccine from the attenuated Sabin strains. In 1959, according to A. Sabin's recommendation, a technology of live vaccine production was developed at the Poliomyelitis Institute, and several experimental lots of vaccine were prepared. In the second part of 1959, 13.5 million children in USSR were immunized. The epidemic poliomyelitis rate decreased 3-5 times in different regions without paralytic cases, which could be attributed to the vaccination. These results were the final proof of high efficiency and safety of live poliomyelitis vaccine from the attenuated Sabin strains. Based on these results, A. Sabin and M. P. Chumakov suggested in 1960 the idea of poliomyelitis eradication using mass immunization of children with live vaccine. 72 million persons up to 20 years old were vaccinated in USSR in 1960 with a 5 times drop in the paralytic rate. 50-year-long use of live vaccine results in poliomyelitis eradication in almost all countries worldwide. More than 10 million children were rescued from the death and palsy. Poliomyelitis eradication in a few countries where it still exists depends not on medical services but is defined by the attitude of their leaders to fight against poliomyelitis. In some developing countries the vaccination data are falsified, thereby threatening the polio epidemics reappearance and the virus spreading to other countries. Methods must be developed for detection and dealing with extremely rare persistent virus carriers. Because of all these constraints the outcome of poliomyelitis eradication at present is uncertain and vaccination must be continued. The world has become poliovaccine dependent.
Asunto(s)
Poliomielitis , Vacunas contra Poliovirus , Femenino , Historia del Siglo XX , Humanos , Masculino , Poliomielitis/epidemiología , Poliomielitis/historia , Poliomielitis/inmunología , Poliomielitis/prevención & control , Vacunas contra Poliovirus/historia , Vacunas contra Poliovirus/inmunología , Vacunas contra Poliovirus/uso terapéutico , Federación de Rusia/epidemiología , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/uso terapéuticoRESUMEN
A major challenge for global rabies prevention and control is the lack of sufficient and affordable high quality vaccines. Such candidates should be pure, potent, safe, effective and economical to produce, with broad cross-reactivity against viral variants of public health and veterinary importance. The history of licensed human vaccines reviewed herein demonstrates clearly how the field has evolved to the current state of more passive development and postexposure management. Modern cell culture techniques provide adequate viral substrates for production of representative verified virus seeds. In contrast to outdated nervous tissue-based rabies vaccines, once a suitable substrate is identified, production of high titer virus results in a major qualitative and quantitative difference. Given the current scenario of only inactivated vaccines for humans, highly cell-adapted and stable, attenuated rabies viruses are ideal candidates for consideration to meet the need for seed viruses in the future.
Asunto(s)
Descubrimiento de Drogas/historia , Descubrimiento de Drogas/tendencias , Vacunas Antirrábicas/inmunología , Rabia/prevención & control , Animales , Técnicas de Cultivo de Célula/historia , Técnicas de Cultivo de Célula/tendencias , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Rabia/inmunología , Vacunas Antirrábicas/historia , Tecnología Farmacéutica/historia , Tecnología Farmacéutica/tendencias , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas de Productos Inactivados/historia , Vacunas de Productos Inactivados/inmunologíaRESUMEN
Many live, attenuated viral vaccines are derived from wild type viruses with known neurovirulent properties. To assure the absence of residual neurotoxicity, pre-clinical neurovirulence safety testing of candidate vaccines is performed. For mumps virus, a highly neurotropic virus, neurovirulence safety testing is performed in monkeys. However, laboratory studies suggest an inability of this test to correctly discern among virus strains of varying neurovirulence potential in man, and, further, some vaccines found to be neuroattenuated in monkeys were later found to be neurovirulent in humans when administered in large numbers. Over the past decade, concerted efforts have been made to replace monkey-based neurovirulence safety testing with more informative, alternative methods. This review summarizes the current status of mumps vaccine neurovirulence safety testing and insights into models currently approved and those under development.
Asunto(s)
Alternativas a las Pruebas en Animales/tendencias , Meningitis Aséptica/inducido químicamente , Vacuna contra la Parotiditis/efectos adversos , Animales , Callithrix , Cricetinae , Haplorrinos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Ratones , Vacuna contra la Parotiditis/historia , Virus de la Parotiditis/patogenicidad , Ratas , Vacunas Atenuadas/efectos adversos , Vacunas Atenuadas/historia , VirulenciaRESUMEN
For centuries, acute diarrhea has been a major worldwide cause of death in young children, and until 1973, no infectious agents could be identified in about 80% of patients admitted to hospital with severe dehydrating diarrhea. In 1973 Ruth Bishop, Geoffrey Davidson, Ian Holmes, and Brian Ruck identified abundant particles of a 'new' virus (rotavirus) in the cytoplasm of mature epithelial cells lining duodenal villi and in feces, from such children admitted to the Royal Children's Hospital, Melbourne. Rotaviruses have now been shown to cause 40-50% of severe acute diarrhea in young children worldwide in both developing and developed countries, and > 600 000 young children die annually from rotavirus disease, predominantly in South-East Asia and sub-Saharan Africa. Longitudinal surveillance studies following primary infection in young children have shown that rotavirus reinfections are common. However the immune response that develops after primary infection is protective against severe symptoms on reinfection. This observation became the basis for development of live oral rotavirus vaccines. Two safe and effective vaccines are now licensed in 100 countries and in use in 17 countries (including Australia). Rotarix (GSK) is a single attenuated human rotavirus, representative of the most common serotype identified worldwide (G1P[8]). RotaTeq (Merck) is a pentavalent mixture of naturally attenuated bovine/human rotavirus reassortants representing G1, G2, G3, G4, and P(8) serotypes. Preliminary surveillance of the numbers of children requiring hospitalization for severe diarrhea, in USA, Brazil, and Australia, after introduction of these vaccines, encourages the hope that rotavirus infection need no longer be a threat to young children worldwide.
Asunto(s)
Diarrea/prevención & control , Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus/administración & dosificación , Rotavirus/patogenicidad , Enfermedad Aguda , Administración Oral , Australia , Preescolar , Diarrea/historia , Diarrea/inmunología , Diarrea/virología , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lactante , Infecciones por Rotavirus/historia , Infecciones por Rotavirus/inmunología , Infecciones por Rotavirus/virología , Vacunas contra Rotavirus/historia , Índice de Severidad de la Enfermedad , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/historiaRESUMEN
Vaccine development, which began with Edward Jenner's observations in the late 18th century, has entered its 4th century. From its beginnings, with the use of whole organisms that had been weakened or inactivated, to the modern-day use of genetic engineering, it has taken advantage of the tools discovered in other branches of microbiology. Numerous successful vaccines are in use, but the list of diseases for which vaccines do not exist is long. However, the multiplicity of strategies now available, discussed in this article, portends even more successful development of vaccines.
Asunto(s)
Bacterias/inmunología , Vacunas Bacterianas/inmunología , Vacunas Atenuadas/inmunología , Vacunas Virales/inmunología , Virus/inmunología , Animales , Vacunas Bacterianas/historia , Vectores Genéticos/inmunología , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Plásmidos/inmunología , Vacunación , Vacunas Atenuadas/historia , Vacunas Virales/historiaAsunto(s)
Alergia e Inmunología/historia , Infecciones por Rotavirus/historia , Vacunas contra Rotavirus/historia , Vacunas Atenuadas/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lactante , Rotavirus/inmunología , Rotavirus/aislamiento & purificación , Infecciones por Rotavirus/inmunología , Infecciones por Rotavirus/prevención & control , Estados UnidosRESUMEN
BACKGROUND: The reduction of childhood mortality by vaccines has been one of the greatest public health successes of the past century. However, many targets for immunization remain uncontrolled, and new or improved vaccines are emerging to meet these challenges. OBJECTIVE: To review the evolution of vaccination and take an objective look at current vaccine development technologies, thereby framing the discussion of vaccine management. SUMMARY: The genesis of vaccinology is generally considered to have been a direct result of the observation that persons who had contracted smallpox rarely developed a second case. From this observation, the concept of variolation was born, which involved the inoculation of uninfected individuals using material collected from smallpox lesions with the goal of inducing immunity to future infection. The use of attenuated, live virus to induce immunity was the next step in the evolution of vaccinology, followed by inactivation of the virus when diseases caused by organisms not amenable to attenuation were targeted. More recently, a variety of adjuvant strategies have been developed to improve the immunogenicity of inactivated vaccines, and genetic engineering has been employed to increase the safety, reduce the reactogenicity, and improve the immunogenicity of different vaccines. CONCLUSION: Clinical (efficacy and safety) and economic (cost and profit) considerations are competing priorities that need to be reconciled within a discussion encompassing the government, the public, the pharmaceutical industry, third-party payers, and private individuals or companies who administer these vaccines.
Asunto(s)
Control de Enfermedades Transmisibles/métodos , Diseño de Fármacos , Vacunas Atenuadas/uso terapéutico , Vacunas de Productos Inactivados/uso terapéutico , Adyuvantes Inmunológicos/uso terapéutico , Análisis Costo-Beneficio , Toma de Decisiones , Ingeniería Genética , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Tecnología Farmacéutica , Vacunas Atenuadas/economía , Vacunas Atenuadas/historia , Vacunas de Productos Inactivados/economía , Vacunas de Productos Inactivados/historiaRESUMEN
Since the Chinese inuented the uaniolation with human pox vaccine and Jenner invented the vaccine for cowpox, the great achievements of vaccination in preventing and treating many diseases are universally acknowledged. In 1995, the New York Academy of Sciences of America sponsored a symposium on DNA (deoxyribonucleic acid) vaccine, which is called the third revolution of vaccine and new epoch for vaccinology. The first revolution was the invention of inactivated vaccines and live attenuated vaccines represented by Pasteur at the end of the nineteenth century. The second one was the subunit of vaccine prepared by DNA recombination technique and techniques of protein chemistry in 1980s.
Asunto(s)
Vacunas Atenuadas/historia , Vacunas de ADN/historia , Vacunas de Productos Inactivados/historia , Historia del Siglo XIX , Historia del Siglo XXAsunto(s)
Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus , Vacuna contra Viruela/historia , Américas , Niño , Historia del Siglo XVIII , Humanos , Islas del Oceano Índico , Intususcepción/etiología , Filatelia , Vacunas contra Rotavirus/efectos adversos , Viruela/historia , Viruela/prevención & control , España , Vacunas Atenuadas/historiaAsunto(s)
Intususcepción/etiología , Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus/efectos adversos , Vacunas contra Rotavirus/historia , Ensayos Clínicos como Asunto , Aprobación de Drogas , Educación Médica Continua , Historia del Siglo XX , Humanos , Lactante , Recién Nacido , Pediatría/educación , Medición de Riesgo , Factores de Riesgo , Vacunas Atenuadas/historiaRESUMEN
Francisella tularensis is a facultative intracellular bacterial pathogen capable of causing a spectrum of human diseases collectively called tularemia. The pathogen is highly infectious and some strains can cause rapidly lethal infection especially when inhaled. The latter were developed as biological weapons in the past and nowadays cause concern as potential bioterrorism agents. A live attenuated strain of the pathogen was developed more that 40 years ago and remains the sole prophylactic measure against the pathogen. Research to develop better live and subunit vaccines is under way. The former will require an understanding of the virulence factors of F. tularensis and a facile means of mutating them and the latter will require identification of the protective antigens of the pathogen. The current vaccine and its potential replacements are the focus of this review.